Novel cytokine-based therapies and methods
AssigneeReverb Therapeutics, Inc.
InventorsDavid DE GRAAF, Mark FOGG, Surjit Bhimarao DIXIT, Stacey TOM-YEW
Life of this patent
Estimating the term…
Abstract
The disclosure relates to methods for redirecting an active form of an endogenous cytokine to a target cell or target tissue of interest in a biological system or subject in need thereof by administering a multi-specific binding molecule comprising (a) a binding domain that specifically binds to an active form of a cytokine and (b) a binding domain that specifically binds to an epitope on a molecule that is a marker on a target cell or tissue, wherein the multi-specific binding molecule, when bound to the cytokine, does not block or only partially blocks, the ability of the cytokine to bind to and agonize a cognate receptor for the cytokine.
Claims25
A method of redirecting an endogenous IL-2 or IL-15 cytokine to a targeted environment of a target cell of a subject, the method comprising:
- administering to the subject a multi-specific construct that comprises:
- (a) a first variable domain directed to the endogenous IL-2 or IL-15 cytokine;
- and
- (b) a second variable domain directed to a target moiety expressed by the target cell,
- wherein the administering results in localization of the endogenous IL-2 or IL-15 cytokine at the targeted environment of the target cell, thereby redirecting the endogenous IL-2 or IL-15 cytokine to the target cell.
A method of redirecting an endogenous interleukin to a targeted environment of a target cell of a subject, the method comprising:
- administering to the subject a multi-specific construct that comprises:
- (a) a first variable domain directed to the endogenous interleukin;
- and
- (b) a second variable domain directed to a target moiety expressed by the target cell that is selected from the group consisting of:
- programmed cell death protein 1 (PD-1), CD33, CD16, programmed death-ligand 1 (PD-L1), an integrin, disialoganglioside (GD2), CD20, fibroblast activation protein (FAP), carcinoembryonic antigen receptor (CEAR), and carcinoembryonic antigen (CEA),
- wherein the administering results in localization of the endogenous interleukin at the targeted environment of the target cell, thereby redirecting the endogenous interleukin to the target cell.
Dependencies are inferred from the claim text.